Abstract 171P
Background
HCC with PVTT portends a worse prognosis. This study compared the efficacy and safety of cTACE plus lenvatinib (cTACE+LEN) to the most commonly utilized regimen, cTACE plus sorafenib (cTACE+SOR), in patients with HCC and PVTT.
Methods
An open-label, single-center, prospective, randomized trial. Patients with previously untreated HCC complicated by type I-IV PVTT were randomized 1:1 to receive cTACE+LEN (LEN orally, 12 or 8 mg/d for bodyweight ≥60 or <60 kg) or cTACE+SOR (SOR orally, 400 mg BID). The primary endpoint was time to progression (TTP; time from randomization to disease progression), secondary endpoints included objective response rate (ORR), overall survival (OS) and toxicity. Tumor response was assessed using mRECIST. Prognostic factors were evaluated with a Cox regression analysis. SPSS v17.0 was used for all analyses.
Results
Between Dec 30, 2018 and May 31, 2020, 64 patients were randomized (cTACE+LEN, n=32; cTACE+SOR, n=32). Patients had a median age of 56 years, a male/female ratio of 13/3, the majority had type I/II PVTT (71.9%; n=46), 34.4% (n=22) had extrahepatic metastasis, and median tumor diameter was 9.0 cm (3.8−21.8). After a median follow-up of 12.5 months, patients in the cTACE+LEN group had a higher median TTP (4.7 vs 3.1 months, HR: 0.55 [95% CI: 0.32–0.97], P=0.037) and numerically higher ORR (50.0 vs 25.0%, P=0.07) and median OS (15.6 [95% CI: 7.7−23.5] vs 10.8 months [95% CI: 8.9−12.7], P=0.15) versus the cTACE+SOR group. A similar incidence of serious adverse events (n=4 vs 2, including gastrointestinal bleeding and hepatic failure), drug withdrawal and dose reduction occurred in the cTACE+LEN and cTACE+SOR groups, and no treatment-related deaths occurred during the study period. Objective response was identified as an independent predictor of favorable TTP (HR: 0.41 [95% CI: 0.22–0.75], P=0.004).
Conclusions
cTACE+LEN was safe, well-tolerated, and had favorable efficacy versus cTACE+SOR for the treatment of advanced HCC with PVTT and large tumor burden. Differences in ORR and OS did not reach statistical significance, which may be due to the limited sample size and requires further study.
Clinical trial identification
NCT04127396.
Editorial acknowledgement
Legal entity responsible for the study
Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Funding
Beijing Hospitals Authority, QML20191805.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session